Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36


Sustained remission with methotrexate monotherapy after 22-week induction treatment with TNF-alpha inhibitor and methotrexate in early psoriatic arthritis: an open-label extension of a randomized placebo-controlled trial.

de Jong HMY, van Mens LJJ, Nurmohamed MT, Kok MR, van Kuijk AWR, Baeten DLP, van de Sande MGH.

Arthritis Res Ther. 2019 Sep 14;21(1):208. doi: 10.1186/s13075-019-1998-4.


Treat to target in PsA should focus on clinical measures. Response to: 'DAPSA versus cDAPSA: do we need use CRP?' by Gonçalves et al.

van Mens LJJ, van de Sande MGH, van Kuijk AWR, Baeten D, Coates LC.

Ann Rheum Dis. 2019 Jul 22. pii: annrheumdis-2019-215990. doi: 10.1136/annrheumdis-2019-215990. [Epub ahead of print] No abstract available.


Achieving remission in psoriatic arthritis by early initiation of TNF inhibition: a double-blind, randomised, placebo-controlled trial of golimumab plus methotrexate versus placebo plus methotrexate.

van Mens LJJ, de Jong HM, Fluri I, Nurmohamed MT, van de Sande MGH, Kok M, van Kuijk AWR, Baeten D.

Ann Rheum Dis. 2019 May;78(5):610-616. doi: 10.1136/annrheumdis-2018-214746. Epub 2019 Feb 26.


Adherence to etanercept therapy in rheumatoid arthritis patients during 3 years of follow-up.

Vogelzang EH, Hebing RCF, Nurmohamed MT, van Kuijk AWR, Kruijff JWF, l'Ami MJ, Krieckaert CLM, Wolbink G.

PLoS One. 2018 Oct 9;13(10):e0205125. doi: 10.1371/journal.pone.0205125. eCollection 2018.


Physician's Global Assessment in Psoriatic Arthritis: A Multicenter GRAPPA Study.

Cauli A, Gladman DD, Mathieu A, Olivieri I, Porru G, Tak PP, Sardu C, Scarpa R, Marchesoni A, Taylor WJ, Salvarani C, Kalden J, Lubrano E, Carneiro S, Piga M, Floris A, Desiati F, Flynn JA, D'Angelo S, van Kuijk AWR, Catanoso MG, Caso F, Contu P, Ujfalussy I, Helliwell PS, Mease PJ; GRAPPA 3PPsA Study Group.

J Rheumatol. 2018 Aug;45(9):1256-1262. doi: 10.3899/jrheum.171183. Epub 2018 Jun 15.


Brief Report: Interleukin-17 Blockade With Secukinumab in Peripheral Spondyloarthritis Impacts Synovial Immunopathology Without Compromising Systemic Immune Responses.

van Mens LJJ, van de Sande MGH, Menegatti S, Chen S, Blijdorp ICJ, de Jong HM, Fluri IA, Latuhihin TE, van Kuijk AWR, Rogge L, Yeremenko NG, Baeten DLP.

Arthritis Rheumatol. 2018 Dec;70(12):1994-2002. doi: 10.1002/art.40581. Epub 2018 Oct 17.


Response to: 'To DAPSA or not to DAPSA? That is not the question' by Schoels et al.

van Mens LJJ, van de Sande MGH, van Kuijk AWR, Baeten DLP, Coates LC.

Ann Rheum Dis. 2019 Jul;78(7):e62. doi: 10.1136/annrheumdis-2018-213618. Epub 2018 May 18. No abstract available.


Ideal target for psoriatic arthritis? Comparison of remission and low disease activity states in a real-life cohort.

van Mens LJJ, van de Sande MGH, van Kuijk AWR, Baeten D, Coates LC.

Ann Rheum Dis. 2018 Feb;77(2):251-257. doi: 10.1136/annrheumdis-2017-211998. Epub 2017 Oct 28.


Residual disease activity and treatment adjustments in psoriatic arthritis in current clinical practice.

van Mens LJJ, van de Sande MGH, Fluri IA, Atiqi S, van Kuijk AWR, Baeten DLP.

Arthritis Res Ther. 2017 Oct 10;19(1):226. doi: 10.1186/s13075-017-1424-8.


Residual disease activity in psoriatic arthritis: discordance between the rheumatologist's opinion and minimal disease activity measurement.

van Mens LJJ, Turina MC, van de Sande MGH, Nurmohamed MT, van Kuijk AWR, Baeten DLP.

Rheumatology (Oxford). 2018 Feb 1;57(2):283-290. doi: 10.1093/rheumatology/kex183.


Reduced CLEC9A expression in synovial tissue of psoriatic arthritis patients after adalimumab therapy.

Ramos MI, Teunissen MB, Helder B, Aarrass S, de Hair MJ, van Kuijk AW, Gerlag DM, Tak PP, Lebre MC.

Rheumatology (Oxford). 2016 Sep;55(9):1575-84. doi: 10.1093/rheumatology/kew204. Epub 2016 May 13.


14-3-3η Autoantibodies: Diagnostic Use in Early Rheumatoid Arthritis.

Maksymowych WP, Boire G, van Schaardenburg D, Wichuk S, Turk S, Boers M, Siminovitch KA, Bykerk V, Keystone E, Tak PP, van Kuijk AW, Landewé R, van der Heijde D, Murphy M, Marotta A.

J Rheumatol. 2015 Sep;42(9):1587-94. doi: 10.3899/jrheum.141385. Epub 2015 Jul 15.


A clinically based protein discovery strategy to identify potential biomarkers of response to anti-TNF-α treatment of psoriatic arthritis.

Collins ES, Butt AQ, Gibson DS, Dunn MJ, Fearon U, van Kuijk AW, Gerlag DM, Pontifex E, Veale DJ, Tak PP, FitzGerald O, Pennington SR.

Proteomics Clin Appl. 2016 Jun;10(6):645-62. doi: 10.1002/prca.201500051. Epub 2015 Sep 28.


Tumour necrosis factor inhibitor monotherapy vs combination with MTX in the treatment of PsA: a systematic review of the literature.

Behrens F, Cañete JD, Olivieri I, van Kuijk AW, McHugh N, Combe B.

Rheumatology (Oxford). 2015 May;54(5):915-26. doi: 10.1093/rheumatology/keu415. Epub 2014 Oct 27. Review.


Discovery and confirmation of a protein biomarker panel with potential to predict response to biological therapy in psoriatic arthritis.

Ademowo OS, Hernandez B, Collins E, Rooney C, Fearon U, van Kuijk AW, Tak PP, Gerlag DM, FitzGerald O, Pennington SR.

Ann Rheum Dis. 2016 Jan;75(1):234-41. doi: 10.1136/annrheumdis-2014-205417. Epub 2014 Sep 3.


Serum 14-3-3η is a novel marker that complements current serological measurements to enhance detection of patients with rheumatoid arthritis.

Maksymowych WP, Naides SJ, Bykerk V, Siminovitch KA, van Schaardenburg D, Boers M, Landewé R, van der Heijde D, Tak PP, Genovese MC, Weinblatt ME, Keystone EC, Zhukov OS, Abolhosn RW, Popov JM, Britsemmer K, van Kuijk AW, Marotta A.

J Rheumatol. 2014 Nov;41(11):2104-13. doi: 10.3899/jrheum.131446. Epub 2014 Aug 15.


Anti-adalimumab antibodies and adalimumab concentrations in psoriatic arthritis; an association with disease activity at 28 and 52 weeks of follow-up.

Vogelzang EH, Kneepkens EL, Nurmohamed MT, van Kuijk AW, Rispens T, Wolbink G, Krieckaert CL.

Ann Rheum Dis. 2014 Dec;73(12):2178-82. doi: 10.1136/annrheumdis-2014-205554. Epub 2014 Aug 12.


A prospective, randomized, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: effects of adalimumab treatment on lesional and nonlesional skin.

de Groot M, Picavet DI, van Kuijk AW, Tak PP, Bos JD, de Rie MA, Teunissen MB.

Dermatology. 2012;225(4):298-303. doi: 10.1159/000343290. Epub 2012 Dec 21.


Expression of IL-20 in synovium and lesional skin of patients with psoriatic arthritis: differential response to alefacept treatment.

Lebre MC, Jonckheere CL, Kraan MC, van Kuijk AW, Bos JD, de Rie M, Gerlag DM, Tak PP.

Arthritis Res Ther. 2012 Sep 24;14(5):R200. doi: 10.1186/ar4038.


Synovial synoviolin in relation to response to TNF blockade in patients with rheumatoid arthritis and psoriatic arthritis.

Klaasen R, Wijbrandts CA, van Kuijk AW, Pots D, Gerlag DM, Tak PP.

Ann Rheum Dis. 2012 Jul;71(7):1260-1. doi: 10.1136/annrheumdis-2011-200741. Epub 2012 Feb 17. No abstract available. Erratum in: Ann Rheum Dis. 2012 Sep;71(9):1592.


Brief report: a phase IIa, randomized, double-blind, placebo-controlled trial of apilimod mesylate, an interleukin-12/interleukin-23 inhibitor, in patients with rheumatoid arthritis.

Krausz S, Boumans MJ, Gerlag DM, Lufkin J, van Kuijk AW, Bakker A, de Boer M, Lodde BM, Reedquist KA, Jacobson EW, O'Meara M, Tak PP.

Arthritis Rheum. 2012 Jun;64(6):1750-5. doi: 10.1002/art.34339. Epub 2011 Dec 14.


Synovitis in psoriatic arthritis: immunohistochemistry, comparisons with rheumatoid arthritis, and effects of therapy.

van Kuijk AW, Tak PP.

Curr Rheumatol Rep. 2011 Aug;13(4):353-9. doi: 10.1007/s11926-011-0181-y. Review.


Patient global assessment in psoriatic arthritis: a multicenter GRAPPA and OMERACT study.

Cauli A, Gladman DD, Mathieu A, Olivieri I, Porru G, Tak PP, Sardu C, Ujfalussy I, Scarpa R, Marchesoni A, Taylor WJ, Spadaro A, Fernàndez-Sueiro JL, Salvarani C, Kalden JR, Lubrano E, Carneiro S, Desiati F, Flynn JA, D'Angelo S, Vacca A, VAN Kuijk AW, Catanoso MG, Gruenke M, Peluso R, Parsons WJ, Ferrara N, Contu P, Helliwell PS, Mease PJ; GRAPPA 3PPsA Study Group.

J Rheumatol. 2011 May;38(5):898-903. doi: 10.3899/jrheum.100857. Epub 2011 Feb 15.


Soluble biomarkers of cartilage and bone metabolism in early proof of concept trials in psoriatic arthritis: effects of adalimumab versus placebo.

van Kuijk AW, DeGroot J, Koeman RC, Sakkee N, Baeten DL, Gerlag DM, Tak PP.

PLoS One. 2010 Sep 3;5(9). pii: e12556. doi: 10.1371/journal.pone.0012556.


CCR5 blockade in rheumatoid arthritis: a randomised, double-blind, placebo-controlled clinical trial.

van Kuijk AW, Vergunst CE, Gerlag DM, Bresnihan B, Gomez-Reino JJ, Rouzier R, Verschueren PC, van der Leij C, Maas M, Kraan MC, Tak PP.

Ann Rheum Dis. 2010 Nov;69(11):2013-6. doi: 10.1136/ard.2010.131235. Epub 2010 Aug 6. Erratum in: Ann Rheum Dis. 2013 Apr;72(4):630. van de Leij, Christiaan [corrected to van der Leij, Christiaan].


Relationship between the clinical response to adalimumab treatment and serum levels of adalimumab and anti-adalimumab antibodies in patients with psoriatic arthritis.

van Kuijk AW, de Groot M, Stapel SO, Dijkmans BA, Wolbink GJ, Tak PP.

Ann Rheum Dis. 2010 Mar;69(3):624-5. doi: 10.1136/ard.2009.108787. No abstract available.


The relationship between synovial lymphocyte aggregates and the clinical response to infliximab in rheumatoid arthritis: a prospective study.

Klaasen R, Thurlings RM, Wijbrandts CA, van Kuijk AW, Baeten D, Gerlag DM, Tak PP.

Arthritis Rheum. 2009 Nov;60(11):3217-24. doi: 10.1002/art.24913.


TWEAK and its receptor Fn14 in the synovium of patients with rheumatoid arthritis compared to psoriatic arthritis and its response to tumour necrosis factor blockade.

van Kuijk AW, Wijbrandts CA, Vinkenoog M, Zheng TS, Reedquist KA, Tak PP.

Ann Rheum Dis. 2010 Jan;69(1):301-4. doi: 10.1136/ard.2008.090548.


A prospective, randomised, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: effects of adalimumab treatment on synovial tissue.

van Kuijk AW, Gerlag DM, Vos K, Wolbink G, de Groot M, de Rie MA, Zwinderman AH, Dijkmans BA, Tak PP.

Ann Rheum Dis. 2009 Aug;68(8):1303-9. doi: 10.1136/ard.2008.091389. Epub 2008 Jul 22.


[Arthritis psoriatica].

de Rie MA, van Kuijk AW, Goedkoop AY, Tak PP.

Ned Tijdschr Geneeskd. 2007 Aug 4;151(31):1716-22. Review. Dutch.


A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis.

Fraser AD, van Kuijk AW, Westhovens R, Karim Z, Wakefield R, Gerards AH, Landewé R, Steinfeld SD, Emery P, Dijkmans BA, Veale DJ.

Ann Rheum Dis. 2005 Jun;64(6):859-64. Epub 2004 Nov 4.


Alefacept therapy reduces the effector T-cell population in lesional psoriatic epidermis.

Goedkoop AY, de Rie MA, Picavet DI, Kraan MC, Dinant HJ, van Kuijk AW, Tak PP, Bos JD, Teunissen MB.

Arch Dermatol Res. 2004 Apr;295(11):465-73. Epub 2004 Feb 14.


Early-onset polyarthritis as presenting feature of intestinal infection with Strongyloides stercoralis.

van Kuijk AW, Kerstens PJ, Perenboom RM, Dijkmans BA, Voskuyl AE.

Rheumatology (Oxford). 2003 Nov;42(11):1419-20. No abstract available.


Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis.

Kraan MC, van Kuijk AW, Dinant HJ, Goedkoop AY, Smeets TJ, de Rie MA, Dijkmans BA, Vaishnaw AK, Bos JD, Tak PP.

Arthritis Rheum. 2002 Oct;46(10):2776-84.


Endothelial dysfunction precedes development of microalbuminuria in IDDM.

Stehouwer CD, Fischer HR, van Kuijk AW, Polak BC, Donker AJ.

Diabetes. 1995 May;44(5):561-4.


Supplemental Content

Loading ...
Support Center